利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.023 秒)

    Prediction of Clinical Outcome in Hematological Malignancies Using a Self-Renewal Expression Signature
    1.
    发明申请
    Prediction of Clinical Outcome in Hematological Malignancies Using a Self-Renewal Expression Signature 审中-公开
    使用自我更新表达签名预测血液恶性肿瘤的临床结果

    公开(公告)号：US20140148351A1

    公开(公告)日：2014-05-29

    申请号：US13825511

    申请日：2011-09-28

    申请人： Arash Ash Alizadeh ,  Ravindra Majeti ,  Andrew J. Gentles

    发明人： Arash Ash Alizadeh ,  Ravindra Majeti ,  Andrew J. Gentles

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/158

    摘要： Methods, compositions, and kits are provided for providing a diagnosis, a prognosis, or a prediction of responsiveness to a therapy for a patient with a hematological malignancy. In practicing the subject methods, the expression level of at least one leukemia stem cell (LSC) genes in a tissue sample is assayed to obtain an LSC expression representation. The LSC expression representation is then employed to determine if an individual has a hematological malignancy, to provide a prognosis to a patient with a hematological malignancy, and/or to provide a prediction of the responsiveness of a patient with a hematological malignancy to a therapy. Also provided are screening methods for identifying novel therapies for patients with a hematological malignancy, and compositions and kits for use in these screening methods.

    摘要翻译： 提供了方法，组合物和试剂盒，用于提供对具有血液恶性肿瘤的患者的治疗的反应性的诊断，预后或预测。 在实施本发明方法中，测定组织样品中至少一种白血病干细胞（LSC）基因的表达水平以获得LSC表达。 然后使用LSC表达表示来确定个体是否具有血液恶性肿瘤，为具有血液恶性肿瘤的患者提供预后，和/或提供患者对于治疗有血液恶性肿瘤的反应性的预测。 还提供了用于鉴定具有血液恶性肿瘤的患者的新疗法的筛选方法，以及用于这些筛选方法的组合物和试剂盒。

    Synergistic anti-CD47 therapy for hematologic cancers
    2.
    发明授权
    Synergistic anti-CD47 therapy for hematologic cancers 有权
    协同抗CD47治疗血液癌

    公开(公告)号：US08758750B2

    公开(公告)日：2014-06-24

    申请号：US13394060

    申请日：2010-09-15

    申请人： Irving L. Weissman ,  Ravindra Majeti ,  Arash Ash Alizadeh ,  Mark P. Chao

    发明人： Irving L. Weissman ,  Ravindra Majeti ,  Arash Ash Alizadeh ,  Mark P. Chao

    IPC分类号： A61K39/395 ,  A61K39/00

    CPC分类号： C07K16/2803 ,  A61K39/39558 ,  A61K51/1093 ,  A61K2039/507 ,  C07K16/2887 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77

    摘要： Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2.

    摘要翻译： 提供了用于治疗血液癌，特别是淋巴瘤和白血病的方法，包括但不限于骨髓性和淋巴细胞性白血病。 CD47特异性抗体的组合; 并向癌症相关细胞表面标志物特异性给予患者，并提供癌细胞负担的协同降低。 抗体的组合可以包含多个单特异性抗体，或双特异性或多特异性抗体。 感兴趣的标记包括但不限于CD20，CD22，CD52，CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; 和HAVCR2。

    Method of Predicting Responsiveness of B Cell Lineage Malignancies to Active Immunotherapy
    7.
    发明申请
    Method of Predicting Responsiveness of B Cell Lineage Malignancies to Active Immunotherapy 有权
    预测B细胞谱系恶性肿瘤对主动免疫治疗反应的方法

    公开(公告)号：US20140220562A1

    公开(公告)日：2014-08-07

    申请号：US13978360

    申请日：2012-01-10

    申请人： Arash Ash Alizadeh ,  Dan Denney ,  Ronald Levy

    发明人： Arash Ash Alizadeh ,  Dan Denney ,  Ronald Levy

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/57426 ,  G01N33/686 ,  G01N2800/52

    摘要： Predictive biomarkers identify those patients suffering from immunoglobulin positive (Ig+) B lineage malignancies that are responsive to active immunotherapy, where the active immunotherapy comprises vaccination with a tumor-specific idiotype-immunogen. It is shown herein that patient responsiveness to the idiotype-immunogen is dependent upon the sequence of the immunogen, where an immunogen having a low number of tyrosine residues in the CDR1 (herein termed CDR1-Y10) regions of one or both of the immunogen heavy and light chains is predictive of a positive anti-tumor response, while a high number of CDR1 tyrosine residues (herein termed CDR1-Yhi) is predictive of a low anti tumor response.

    摘要翻译： 预测性生物标志物识别患有对主动免疫治疗有反应的免疫球蛋白阳性（Ig +）B谱系恶性肿瘤的患者，其中主动免疫治疗包括用肿瘤特异性独特型免疫原接种疫苗。 在本文中显示，患者对独特型免疫原的反应性取决于免疫原的序列，其中免疫原重量的一个或两个的CDR1（本文中称为CDR1-Y10）区域中具有低数量酪氨酸残基的免疫原 轻链可预测阳性的抗肿瘤反应，而大量的CDR1酪氨酸残基（这里称为CDR1-Yhi）预示着低的抗肿瘤反应。